Ultragenyx Pharmaceutical(RARE) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of$98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of$530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-u ...